Forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the
"PSLRA") are included in our Form 10-K. The words or phrases "believes," "may," "will," "expects," "should,"
"continue," "anticipates," "intends," "will likely result," "estimates," "projects" or similar expressions identify
forward-looking statements in our Form 10-K and in our future filings with the Securities and Exchange
Commission, in our press releases, in our presentations to securities analysts or investors, and in oral statements
made by or approved by an executive officer of Diametrics Medical, Inc. Forward-looking statements involve
risks and uncertainties that may materially and adversely affect our business, results of operations, financial
condition or prospects, and may cause our actual results to differ materially from historical results or the results
discussed in the forward-looking statements.
You should consider carefully the following cautionary statements if you own our common stock or are planning
to buy our common stock. We intend to take advantage of the "safe harbor" provisions of the PSLRA by
providing this discussion. We are not undertaking to address or update each factor in future filings or
communications regarding our business or results except to the extent required by law.
We are at an early stage of commercialization with limited operating history
Founded in 1990, we were engaged primarily in the research, development and testing of, and the development
of manufacturing capabilities for, the IRMA(R) (Immediate Response Mobile Analysis) System and the Paratrend
(R) 7 until 1995. Since then, we have developed and are marketing product line extensions from both of these
core technology platforms, primarily an expansion of the blood analysis test menu available on the IRMA System,
and the extension of the continuous monitoring technology available on the Paratrend 7 to two new continuous
monitoring products, Neotrend(TM)